[优化晚期泌尿系统恶性肿瘤的治疗] - Suppr

Suppr

超能文献

[Optimizing treatment of advanced urologic malignancies].

作者信息

Heidenreich A, Ohlmann C H, Ozgür E, Pfister D, Sahi D, Thüer D, Engelmann U H

机构信息

Klinik und Poliklinik für Urologie, Uniklinik, Kerpener Strasse 62, 50924 Köln.

出版信息

Urologe A. 2007 Sep;46(9):1278-84. doi: 10.1007/s00120-007-1396-4.

DOI:10.1007/s00120-007-1396-4

PMID:17628781

Abstract

摘要

相似文献

[Optimizing treatment of advanced urologic malignancies].

Urologe A. 2007 Sep;46(9):1278-84. doi: 10.1007/s00120-007-1396-4.

[Evaluation of gene therapy in the treatment of urological tumors].

Urologe A. 1999 Nov;38(6):603-13. doi: 10.1007/s001200050335.

Clinical innovations in urologic oncology.

Int J Urol. 1996 Jan;3(1 Suppl):S40. doi: 10.1111/j.1442-2042.1996.tb00082.x.

Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?

Int Urol Nephrol. 2016 May;48(5):671-80. doi: 10.1007/s11255-016-1226-y. Epub 2016 Feb 3.

Treatment of bone metastases in urologic malignancies.

Urol Int. 2014;93(3):249-56. doi: 10.1159/000365788. Epub 2014 Aug 7.

The role of methylation in urological tumours.

Arch Esp Urol. 2013 Jun;66(5):432-9.

A new standard of care for advanced-stage urothelial carcinoma.

Nat Rev Clin Oncol. 2024 May;21(5):336. doi: 10.1038/s41571-024-00884-0.

[Tumor markers in the histopathology of urologic tumors].

Urologe A. 1987 Jan;26(1):2-6.

[Response criteria for urological cancer treatment].

Nihon Hinyokika Gakkai Zasshi. 1992 Apr;83(4):447-72.

[Secondary prevention after urological cancers. What are the pertinent facts about aftercare?].

Urologe A. 2007 Jun;46(6):642-5. doi: 10.1007/s00120-007-1343-4.

本文引用的文献

Novel targets and approaches in advanced prostate cancer.

Curr Opin Urol. 2007 May;17(3):182-7. doi: 10.1097/MOU.0b013e3280dd8a4f.

Targeting metastatic prostate cancer: the search for innovative systemic therapies.

Oncology (Williston Park). 2006 Dec;20(14):1787-91; discussion 1791-6.

Palliative transurethral resection of the prostate: functional outcome and impact on survival.

BJU Int. 2007 Jan;99(1):56-9. doi: 10.1111/j.1464-410X.2006.06529.x. Epub 2006 Oct 11.

Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia.

Leuk Res. 2007 Apr;31(4):531-9. doi: 10.1016/j.leukres.2006.07.013. Epub 2006 Aug 30.

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

Oncogene. 2006 Oct 5;25(45):6113-22. doi: 10.1038/sj.onc.1209632. Epub 2006 May 1.

Recent advances in management of patients with platinum-refractory testicular germ cell tumors.

Cancer. 2006 Mar 15;106(6):1217-26. doi: 10.1002/cncr.21742.

Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.

Int J Oncol. 2006 Feb;28(2):375-81.

Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Genes Chromosomes Cancer. 2006 Apr;45(4):365-74. doi: 10.1002/gcc.20300.

Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review.

Eur Urol. 2005 Jul;48(1):60-7; discussion 67-8. doi: 10.1016/j.eururo.2005.03.025. Epub 2005 Apr 7.

Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor.

J Clin Oncol. 2005 Apr 1;23(10):2358-65. doi: 10.1200/JCO.2005.03.084.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验